By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Editas Medicine 

300 Third Street, First Floor

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-401-9000 Fax: n/a


Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.

The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.




Founders: Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David Liu

CEO: Karine Bosley

CFO: Andrew Hack

COO: Alexandra Glucksmann

CTO: Vic Myer


Please click here for Editas Medicine job opportunities.


Key Statistics

Ownership: Public

Web Site: Editas Medicine
Employees: n/a
Symbol: EDIT


Start Up

Company News
Turns Out Editas Medicine (EDIT)'s R&D Deal With Allergan (AGN) Could be Worth $1 Billion 3/23/2017 6:03:11 AM
Third Rock Ventures Quietly Launches Tango Therapeutics in Editas Medicine (EDIT)’s HQ 3/7/2017 6:11:22 AM
COO and First Employee of Editas Medicine (EDIT) to Exit, Effective March 31 3/6/2017 5:32:02 AM
Editas Medicine (EDIT) to Pay Six Academic Centers for Exclusive Rights to a New System That Might Improve CRISPR-Cas9 12/20/2016 6:51:40 AM
Editas Medicine (EDIT) Brings on New Execs From Sanofi Genzyme (SNY), Novartis AG (NVS), Baxalta (BXLT) and Bristol-Myers Squibb (BMY) 10/5/2016 7:19:35 AM
Editas Medicine (EDIT) Nabs Former Bristol-Myers Squibb (BMY) Exec as New CSO 8/22/2016 6:40:18 AM
Editas Medicine Appoints Akshay Vaishnaw, M.D., Ph.D., To Its Board Of Directors 7/29/2016 8:45:13 AM
10 Biotech Stocks Analysts are Upbeat About in May 5/23/2016 8:24:58 AM
Editas Medicine And Radius Health (RDUS) Choose Mass Innovation Labs For Rapid Start And Operational Capabilities 5/4/2016 11:09:21 AM
Editas Medicine And Radius Health (RDUS) Choose Mass Innovation Labs For Rapid Start And Operational Capabilities 5/3/2016 10:32:24 AM